Earnings Summary

Kaman Corporation’s revenue jumped 3.03% since last year same period to $203.12Mn in the Q4 2023. On a quarterly growth basis, Kaman Corporation has generated 10.98% jump in its revenue since last 3-months.

Kaman Corporation’s net profit jumped 103.63% since last year same period to $2Mn in the Q4 2023. On a quarterly growth basis, Kaman Corporation has generated 36.08% jump in its net profits since last 3-months.

Kaman Corporation’s net profit margin jumped 103.52% since last year same period to 0.98% in the Q4 2023. On a quarterly growth basis, Kaman Corporation has generated 22.62% jump in its net profit margins since last 3-months.

Kaman Corporation’s price-to-earnings ratio after this Q4 2023 earnings stands at 164.25.

Kaman Corporation’s earning per share (EPS) estimates for the current quarter stand at 0.12 - a -14.29% fall from last quarter’s estimates.

Kaman Corporation’s earning per share (EPS) estimates for the current year stand at 0.12.

Kaman Corporation’s earning per share (EPS) fell -71.43% since last year same period to 0.12 in the Q4 2023. This indicates that the Kaman Corporation has generated -71.43% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Kaman Corporation’s return on assets (ROA) stands at 0.02.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Kaman Corporation’s return on equity (ROE) stands at 0.01.

Kaman Corporation declared 0.2 dividend per share during the earnings announcement for Q4 2023.